Bentley has announced the US launch of its BeBack crossing catheter, which is designed for the treatment of heavily calcified lesions. This is the company’s first product to be launched in the USA.
A press release notes that, after the acquisition of the GoBack catheter in September 2022, Bentley worked behind the scenes on the rebranding of the device from GoBack to BeBack, making sure the device would benefit from the Bentley corporate branding.
The BeBack catheter—available in 80cm and 120cm lengths and in sizes of 2.9Fr and 4Fr—is designed for steering through chronic total occlusions (CTOs). The device makes use of a steerable and adjustable (in length) Nitinol needle, which is used for crossing and targeted re-entry purposes. A radiopaque marker indicates the direction in which the curved needle, located near the tip of the catheter, protrudes. Multiple treatment options from antegrade, retrograde and crossover are possible with the BeBack crossing catheter for intraluminal and subintimal approaches of stenotic or occluded lesions, the company details.
Robert Beasley (Palm Vascular Centers Miami Beach, Miami Beach, USA) was the first to use the BeBack in the USA. “Now that the BeBack is available I use it more frequently compared to other re-entry devices that are available on the market. The unique features of the BeBack make the most complex lesions easy to cross, and therefore the device helps to reduce the procedure time,” he said. “Reducing the procedure time is of huge benefit for both the clinical centre, the physician and of course for the patients, who will benefits the most. This and the unique features makes the BeBack such a game changer for CTO procedures.”
Bentley advises that the BeBack crossing catheter is now commercially available nationwide and that the device will be showcased and presented at several upcoming conferences both nationally and internationally.
The BeBack is CE marked and US Food and Drug Administration (FDA) cleared for commercial purposes, the company adds.
